The Investment Journal</ti= tle><o:SmartTagType namespaceuri=3Durn:schemas-microsoft-com:office:smartt= ags name=3D"date"/><o:SmartTagType namespaceuri=3Durn:schemas-microsoft-co= m:office:smarttags name=3D"place"/><o:SmartTagType namespaceuri=3Durn:sche= mas-microsoft-com:office:smarttags name=3D"country-region"/><o:SmartTagTyp= e namespaceuri=3Durn:schemas-microsoft-com:office:smarttags name=3D"City"/= ><style>= </style></head><body lang=3DEN-US link=3Dblue vlink=3Dpurple style=3Dtab-i= nterval:.5in><div class=3DSection1><div align=3Dcenter><table class=3DMsoN= ormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 width=3D591 style=3D= 'width:443.45pt;margin-left:.45in;background:#E5D68D;border-collapse: collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt;background-position-x:0%; background-position-y: 50%;background-attachment:scroll'><tr style=3Dmso-yfti-irow:0;mso-yfti-las= trow:yes;height:77.25pt><td width=3D591 nowrap valign=3Dtop style=3D'width= :443.45pt;padding:0in 5.4pt 0in 5.4pt; height:77.25pt'><h3>The Investment</h3>Issue 23=FFFFFFA0=FFFFFFA0=FFF= FFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFF= FA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA= 0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0 Journal=FFFFFFA0=FFFFFFA0=FFFFFFA0 April 2002<o:p></o:p><= /span></td></tr></table></div><o:p>&nbs= p;</o:p>=FFFFF= FA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0 BIOTECH HOLDINGS LT= D.<o:p></o:p><o:p> </o:p><table class=3D= MsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 style=3D'border-= collapse:collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'><tr style=3Dmso-yft= i-irow:0;mso-yfti-lastrow:yes;height:549.0pt><td width=3D431 valign=3Dtop = style=3D'width:323.6pt;padding:0in 5.4pt 0in 5.4pt; height:549.0pt'><table class=3DMsoNormalTable border=3D0 cellspacing=3D0 c= ellpadding=3D0 style=3D'background:#E5D68D;border-collapse:collapse;mso-pa= dding-alt:0in 5.4pt 0in 5.4pt'><tr style=3Dmso-yfti-irow:0;mso-yfti-lastro= w:yes><td width=3D405 valign=3Dtop style=3D'width:303.4pt;padding:0in 5.4p= t 0in 5.4pt'><h1 align=3Dcenter style=3Dtext-align:center>BIOTECH HOLDINGS PROFILE= <o:p></o:p></h1><h1 align=3Dcenter style=3Dtext-align:center><span= lang=3DEN-CA style=3D'font-family:"Calisto MT";color:green'>=FFFFFFA0BREAKTHROUGH DIABETES DRUG<o:p></o:p></h1></td></tr></table><h1 align=3Dce= nter style=3Dtext-align:center><o= :p> </o:p></h1>The Company: Biotech is a pharmaceutical company based in </= span><st1:place><st1:City>Vancouver</st1:City>, <st1:country-region>= Canada</st1:country-region></st1:place>.=FFFFFFA0 Biotech controls and is bringi= ng to market a breakthrough diabetes drug.=FFFFFFA0 The drug, called DIAB II, is classed as an insulin-sen= sitizing drug. Drugs of this type improve the body=FFFFFF92s ability<o:p><= /o:p>to make use of insulin, = the hormone that controls blood sugar levels.=FFFFFFA0 Currently available insulin-sensitizers such as Avandia and Actos have hu= ge sales volumes=FFFFFF= A0 -- over $700 million annually in the case of Avandia, and over $1 Billion for A= ctos=FFFFFFA0 -- despite = a number of drawbacks including potential liver toxicity.=FFFFFFA0 The success of these drugs demonstrates the= tremendous potential for an effective and safe insulin sensitizer such as= DIAB II.<o:p></o:p> <o:p></o:p= >= The Potential Market: The market for Type II Diabetes drug worldwide is es= timated to be more than $10 billion annually.<o:p>= </o:p> <o:p></o:p>Biotech=FFFFFF92s first goal is to = bring DIAB II onto the market in <st1:place>Latin America</st1:place>, as preparation for br= inging DIAB II to the drug market in the <st1:country-region><st1:p= lace>U.S.</st1:place></st1:country-region> and </spa= n><st1:country-region><st1:place>Canada</st1:place></st1:country-region>. Dis= cussions with potential pharmaceutical partners for the <st1:co= untry-region><st1:place>U.S.</st1:place></st1:country-region> ma= rket have begun.<o:p></o:p> <o:p></o:p>In <st1:place>Latin America</st1:place>, <st1:country-r= egion><st1:place>Mexico</st1:place></st1:country-region> is firs= t on the company=FFFFFF92s list of target markets. In his report to shareh= olders issued <st1:date Month=3D3 Day=3D1 Year=3D2002>= March 1, 2002</st1:date>, the President of Biotech Holdings, Robert <spa= n class=3DSpellE>Rieveley, said: We believe that we are well pos= itioned for receiving regulatory approval shortly.=FFFFFFA0 Accordingly, we have been making preparations for = supply of DIAB II to the Mexican market, which is the eighth largest pharm= aceutical market in the world.<o:p></o:p> <o:p></o:p></s= pan>In </= span><st1:place>Latin America</st1:place>, DIAB II has already b= een approved in <st1:country-region><st1:place>Peru</s= pan></st1:place></st1:country-region> and Biotech has signed = distribution agreements for <st1:country-region><st1:place><span= lang=3DEN-CA style=3D'font-size:9.0pt;mso-bidi-font-size:10.0pt;font-fami= ly: Arial'>Venezuela</st1:place></st1:country-region>= , <st1:country-region><st1:place>Chile</= b></st1:place></st1:country-region> and <st1:co= untry-region><st1:place>Argentina</st1:place></= st1:country-region>.=FFFFFFA0 = In other markets, a distributor has been signed for <st1:cou= ntry-region><st1:place>Turkey</st1:place></st1:= country-region> and preliminary agreements are in place for <= /span><st1:country-region><st1:place>Spain</st1:place></st1:country-region>, = <st1:country-region><st1:place>Greece</b= ></st1:place></st1:country-region>, <st1:countr= y-region><st1:place>South Africa</st1:place></s= t1:country-region> and several markets in the <st1:pla= ce>Middle East</st1= :place> and <st1:place>South Asia</st1:place>.</spa= n><o:p></o:p> <o:p></o:p><p= class=3DMsoNormal style=3Dtext-align:justify>The <st1= :country-region><st1:place>U.S.</st1:place></st1:country-region> pa= tents that protect DIAB II - - issued on <st1:date Month=3D11 Day=3D= 28 Year=3D2000>November 28, 2000</st1:date> and </= span><st1:date Month=3D9 Day=3D18 Year=3D2001>September 18, 2001</st= 1:date> - - confer the sole right to the use of treatments co= mbining insulin-sensitizing drugs with any other standard medications for = Type II Diabetes.=FFFFFFA0 Many l= arge pharmaceutical companies active in the diabetes field may be affected= <o:p></o:p> <o:p></o:p></spa= n>In addi= tion to its prescription drug business, Biotech has a non-prescription, pe= rsonal care products division which is showing steady growth.=FFFFFFA0 In addition to its growing private label= business, this division is planning to launch a new line of high-margin c= osmetic products, which will be sold primarily in the <st1:country-= region><st1:place>U.S.</st1:place></st1:country-region><o:p></o:p= >&= nbsp;<o:p></o:p>Biotech=FFFFFF92s revenues are set to grow= sharply as markets for DIAB II open up, as non-prescription rev= enues grow and as the implications of the above-mentioned patents are = pursued, with potential for royalty payments from major pharmaceutical = companies. In his Report to Shareholders, the President of Biotech con= cluded: We look forward with enthusiasm to developments in the coming m= onths.<o:p></o:p></p= ><h1 align=3Dleft style=3Dtext-align:left><o:p> </o:p></h1></td><td width=3D327 valign=3Dt= op style=3D'width:245.2pt;padding:0in 5.4pt 0in 5.4pt; height:549.0pt'><table class=3DMsoNormalTable border=3D0 cellspacing=3D0 c= ellpadding=3D0 align=3Dleft width=3D323 style=3D'width:242.6pt;border-coll= apse:collapse;mso-table-overlap: never;mso-table-lspace:9.0pt;margin-left:6.75pt;mso-table-rspace:9.0pt; margin-right:6.75pt;mso-table-anchor-vertical:paragraph;mso-table-anchor-h= orizontal: margin;mso-table-left:left;mso-table-top:97.8pt;mso-padding-alt:0in 5.4pt = 0in 5.4pt'><tr style=3Dmso-yfti-irow:0><td width=3D179 valign=3Dtop style=3D= 'width:134.6pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;background:green;padding:0in 5.4pt 0i= n 5.4pt'>Company Name<o:p></o:= p></td><td width=3D144 valign=3Dtop style=3D'width:1.5in;border= :solid windowtext 1.0pt; border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>Biotech Holdings Ltd.<o:p></o:p><= /span></td></tr><tr style=3Dmso-yfti-irow:1><td width=3D179 valign= =3Dtop style=3D'width:134.6pt;border:solid windowtext 1.0pt; border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-botto= m-alt: solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Stock Exchange in U.S= <o:p></o:p></td><td width=3D144 valign=3Dtop style=3D'width:1.5= in;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.= 0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowt= ext .5pt; mso-border-alt:solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt = 0in 5.4pt'>OTC BB: BIOHF<= span lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-b= idi-font-family: Arial'><o:p></o:p></td></tr><tr style=3Dmso-yfti-irow:2><td wid= th=3D179 valign=3Dtop style=3D'width:134.6pt;border:solid windowtext 1.0pt= ; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt'>Stock Exchange in </s= pan><st1:country-region><st1:place>Canada</st1:place></st1:country-region><o:p></o:p></td><td width=3D144 valign=3Dtop= style=3D'width:1.5in;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.= 0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowt= ext .5pt; mso-border-alt:solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt = 0in 5.4pt'>TS= X.Venture: BIO<o:p></o:p></p= ></td></tr><tr style=3Dmso-yfti-irow:3><td width=3D179 valign=3Dtop style=3D= 'width:134.6pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt'>52-week High/Low BIOH= F<o:p></o:p></td><td width=3D144 valign=3Dtop style=3D'width:1.= 5in;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.= 0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowt= ext .5pt; mso-border-alt:solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt = 0in 5.4pt'>$.41/$0.07<spa= n lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-bidi= -font-family: Arial'><o:p></o:p></td></tr><tr style=3Dmso-yfti-irow:4;mso-yft= i-lastrow:yes><td width=3D179 valign=3Dtop style=3D'width:134.6pt;border:s= olid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt'>52-week High/Low BIO<= o:p></o:p></td><td width=3D144 valign=3Dtop style=3D'width:1.5i= n;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.= 0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowt= ext .5pt; mso-border-alt:solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt = 0in 5.4pt'>$.65/$.12<span= lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-bidi-= font-family: Arial'><o:p></o:p></td></tr></table><o:p> </o:p><o:p> </o:p>= <o:p> </o:p><o:p>&= nbsp;</o:p><o:p> <= /o:p><o:p> </o:p><= /span><table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpad= ding=3D0 style=3D'background:#E5D68D;border-collapse:collapse;mso-padding-= alt:0in 5.4pt 0in 5.4pt'><tr style=3Dmso-yfti-irow:0;mso-yfti-lastrow:yes>= <td width=3D324 valign=3Dtop style=3D'width:242.65pt;padding:0in 5.4pt 0in= 5.4pt'><h1 align=3Dleft style=3D'text-align:left;tab-stops:12.75pt center= 115.9pt'>=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFF= FA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA= 0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0 THE <st1:place>OPPORTUNITY</sp= an></st1:place><o:p></o:p></h1></td></tr></table><o:p> </o:= p><h1 align=3Dcenter style=3Dtext-align:center>There has been growing investor interest and substantial volumes in = trading of BIOHF shares.=FFFFFFA0 Si= nce January 2002 trading has averaged nearly 1 million shares per week.<sp= an style=3Dmso-spacerun:yes>=FFFFFFA0 This suggests to some market = watchers that a strong base is being formed, with the next step being a si= gnificant upward movement.=FFFFFFA0=FFFFFFA= 0 Research the growth potential of this special situation while the= Company that developed, controls and markets DIAB II is still trading as = a penny stock.<o:p></o:p></h1><o:p> </o:p>= <o:p> </o:p><table class=3DMsoNormalTable border=3D0 cells= pacing=3D0 cellpadding=3D0 style=3D'background:#E5D68D;border-collapse:col= lapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'><tr style=3Dmso-yfti-irow:0;mso= -yfti-lastrow:yes><td width=3D324 valign=3Dtop style=3D'width:242.65pt;pad= ding:0in 5.4pt 0in 5.4pt'><h2 align=3Dcenter style=3Dtext-align:center><sp= an lang=3DEN-CA style=3D'font-family:"Calisto MT";color:green'>INVESTOR IN= FORMATION<o:p></o:p><= /h2></td></tr></table><o:p> </o:p><table class=3DMsoNormalTable= border=3D0 cellspacing=3D0 cellpadding=3D0 width=3D332 style=3D'width:249= 0pt;border-collapse:collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'><tr sty= le=3Dmso-yfti-irow:0><td width=3D192 valign=3Dtop style=3D'width:144.2pt;b= order:none;border-bottom: solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Active Float:<o:p></o:p></td><td widt= h=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border-bottom: solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>20,000,000<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:1><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'><st1:country-region><st1:place>U.S.</st1:place></st1:country-region> SEC Registration No.:<o:p></o:p><= /p></td><td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;bo= rder-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>0 - 29108<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:2><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Shares outstandingMar.31/02:<o:p></o:p><= /p></td><td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;bo= rder-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>69,928,130<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:3><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Recent Market Cap:<o:p></o:p></td><= td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border-bott= om: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>$6,300,000 US<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:4><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Stock Exchange in <st1:country-region><st1:place><span= lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-bidi-= font-family: Arial;color:white'>U.S.</st1:place></st1:country-region>:<o:p></o:p></td><td widt= h=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>OTC BB: BIOHF<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:5><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Stock Exchange in <st1:country-region><st1:place><span= lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-bidi-= font-family: Arial;color:white'>Canada</st1:place></st1:country-region>:<o:p></o:p></td><td widt= h=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>TSX.Venture:BIO<span= lang=3DEN-CA style=3Dfont-size:10.0pt;mso-bidi-font-size:12.0pt><o:p></o:= p></td></tr><tr style=3Dmso-yfti-irow:6><td width=3D192 valign=3D= top style=3D'width:144.2pt;border:none;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>52-week High/Low BIOHF:<o:p></o:p><= /td><td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border= -bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>$.41/$0.07<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:7;mso-yfti-lastrow:yes;height:3.5pt><td width=3D192 valign=3Dto= p style=3D'width:144.2pt;border:none;mso-border-top-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt; height:3.5pt'>52-week High/Low BIO:<o:p></o:p></td><= td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;mso-border-= top-alt: solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt 0in 5.4pt; height:3.5pt'>$.65/$.12<o:p></o:p></td></tr></table><o:p> </o:p>= =FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFF= FA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA= 0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FF= FFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFF= FFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFF= A0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0= =FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0</td></tr></tabl= e>Th= e Investment Journal: The information herein has been obtained from source= s which are believed to be reliable, but there are no guarantees as to its= accuracy or completeness. Neither the information nor any opinion express= ed constitutes a solicitation for the purchase or sale of any security. Bi= otech Holdings has not paid any cash or shares for its appearance on this = report.=FFFFFFA0 Some or all employe= es at The Investment Journal may hold shares in companies featured. We do = not recommend or constitute "buy" or "sell" signals or= advisories for our readers. The Investment Journal is not a securities br= oker-dealer, investment advisor or a securities exchange and is not regist= ered as such with the Securities and Exchange Commission nor any state securities regulation authority. Consult with your= financial advisor before making any financial decisions.This Newsletter is inte= nded for our opt-in readers only. If you have received this email in error= ,<o:p></o:p>=FFFFFFA0you may remove your address by e-mailing <a = href=3Dmailto:theinvestmentjournal@excite.com?subject=3DRemove>theinvestme= ntjournal@excite.com</a>.<o:p></o:p><o:p> </o:p><= /div></body></html>

From mboxrd@z Thu Jan 1 00:00:00 1970 Path: main.gmane.org!not-for-mail From: "The Investment Journal" Newsgroups: gmane.emacs.bugs,gmane.spam.detected Subject: The Investment Journal: Biotech Holdings Ltd. GTX Date: Mon, 22 Apr 2002 22:24:17 -1700 Sender: bug-gnu-emacs-admin@gnu.org Message-ID: Reply-To: TIJournal646@eudoramail.com NNTP-Posting-Host: localhost.gmane.org Mime-Version: 1.0 Content-Type: text/html; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable X-Trace: main.gmane.org 1019728142 4008 127.0.0.1 (25 Apr 2002 09:49:02 GMT) X-Complaints-To: usenet@main.gmane.org NNTP-Posting-Date: Thu, 25 Apr 2002 09:49:02 +0000 (UTC) Return-path: Original-Received: from fencepost.gnu.org ([199.232.76.164]) by main.gmane.org with esmtp (Exim 3.33 #1 (Debian)) id 170fs5-00012F-00 for ; Thu, 25 Apr 2002 11:49:01 +0200 Original-Received: from localhost ([127.0.0.1] helo=fencepost.gnu.org) by fencepost.gnu.org with esmtp (Exim 3.34 #1 (Debian)) id 170fs7-0006pF-00; Thu, 25 Apr 2002 05:49:03 -0400 Original-Received: from [211.154.129.51] (helo=powerlea-e7bcbx) by fencepost.gnu.org with esmtp (Exim 3.34 #1 (Debian)) id 170fpE-0006a2-00; Thu, 25 Apr 2002 05:46:05 -0400 Original-Received: from xmxpita.excite.com [205.184.133.141] by powerlea-e7bcbx with ESMTP (SMTPD32-6.04) id A86E3600B6; Wed, 24 Apr 2002 11:37:18 +0800 Original-To: Errors-To: bug-gnu-emacs-admin@gnu.org X-BeenThere: bug-gnu-emacs@gnu.org X-Mailman-Version: 2.0.9 Precedence: bulk List-Help: List-Post: List-Subscribe: , List-Id: Bug reports for GNU Emacs, the Swiss army knife of text editors List-Unsubscribe: , List-Archive: Xref: main.gmane.org gmane.emacs.bugs:934 gmane.spam.detected:15504 X-Report-Unspam: http://unspam.gmane.org/gmane.emacs.bugs:934 The Investment Journal</ti= tle><o:SmartTagType namespaceuri=3Durn:schemas-microsoft-com:office:smartt= ags name=3D"date"/><o:SmartTagType namespaceuri=3Durn:schemas-microsoft-co= m:office:smarttags name=3D"place"/><o:SmartTagType namespaceuri=3Durn:sche= mas-microsoft-com:office:smarttags name=3D"country-region"/><o:SmartTagTyp= e namespaceuri=3Durn:schemas-microsoft-com:office:smarttags name=3D"City"/= ><style>= </style></head><body lang=3DEN-US link=3Dblue vlink=3Dpurple style=3Dtab-i= nterval:.5in><div class=3DSection1><div align=3Dcenter><table class=3DMsoN= ormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 width=3D591 style=3D= 'width:443.45pt;margin-left:.45in;background:#E5D68D;border-collapse: collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt;background-position-x:0%; background-position-y: 50%;background-attachment:scroll'><tr style=3Dmso-yfti-irow:0;mso-yfti-las= trow:yes;height:77.25pt><td width=3D591 nowrap valign=3Dtop style=3D'width= :443.45pt;padding:0in 5.4pt 0in 5.4pt; height:77.25pt'><h3>The Investment</h3>Issue 23=FFFFFFA0=FFFFFFA0=FFF= FFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFF= FA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA= 0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0 Journal=FFFFFFA0=FFFFFFA0=FFFFFFA0 April 2002<o:p></o:p><= /span></td></tr></table></div><o:p>&nbs= p;</o:p>=FFFFF= FA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0 BIOTECH HOLDINGS LT= D.<o:p></o:p><o:p> </o:p><table class=3D= MsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 style=3D'border-= collapse:collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'><tr style=3Dmso-yft= i-irow:0;mso-yfti-lastrow:yes;height:549.0pt><td width=3D431 valign=3Dtop = style=3D'width:323.6pt;padding:0in 5.4pt 0in 5.4pt; height:549.0pt'><table class=3DMsoNormalTable border=3D0 cellspacing=3D0 c= ellpadding=3D0 style=3D'background:#E5D68D;border-collapse:collapse;mso-pa= dding-alt:0in 5.4pt 0in 5.4pt'><tr style=3Dmso-yfti-irow:0;mso-yfti-lastro= w:yes><td width=3D405 valign=3Dtop style=3D'width:303.4pt;padding:0in 5.4p= t 0in 5.4pt'><h1 align=3Dcenter style=3Dtext-align:center>BIOTECH HOLDINGS PROFILE= <o:p></o:p></h1><h1 align=3Dcenter style=3Dtext-align:center><span= lang=3DEN-CA style=3D'font-family:"Calisto MT";color:green'>=FFFFFFA0BREAKTHROUGH DIABETES DRUG<o:p></o:p></h1></td></tr></table><h1 align=3Dce= nter style=3Dtext-align:center><o= :p> </o:p></h1>The Company: Biotech is a pharmaceutical company based in </= span><st1:place><st1:City>Vancouver</st1:City>, <st1:country-region>= Canada</st1:country-region></st1:place>.=FFFFFFA0 Biotech controls and is bringi= ng to market a breakthrough diabetes drug.=FFFFFFA0 The drug, called DIAB II, is classed as an insulin-sen= sitizing drug. Drugs of this type improve the body=FFFFFF92s ability<o:p><= /o:p>to make use of insulin, = the hormone that controls blood sugar levels.=FFFFFFA0 Currently available insulin-sensitizers such as Avandia and Actos have hu= ge sales volumes=FFFFFF= A0 -- over $700 million annually in the case of Avandia, and over $1 Billion for A= ctos=FFFFFFA0 -- despite = a number of drawbacks including potential liver toxicity.=FFFFFFA0 The success of these drugs demonstrates the= tremendous potential for an effective and safe insulin sensitizer such as= DIAB II.<o:p></o:p> <o:p></o:p= >= The Potential Market: The market for Type II Diabetes drug worldwide is es= timated to be more than $10 billion annually.<o:p>= </o:p> <o:p></o:p>Biotech=FFFFFF92s first goal is to = bring DIAB II onto the market in <st1:place>Latin America</st1:place>, as preparation for br= inging DIAB II to the drug market in the <st1:country-region><st1:p= lace>U.S.</st1:place></st1:country-region> and </spa= n><st1:country-region><st1:place>Canada</st1:place></st1:country-region>. Dis= cussions with potential pharmaceutical partners for the <st1:co= untry-region><st1:place>U.S.</st1:place></st1:country-region> ma= rket have begun.<o:p></o:p> <o:p></o:p>In <st1:place>Latin America</st1:place>, <st1:country-r= egion><st1:place>Mexico</st1:place></st1:country-region> is firs= t on the company=FFFFFF92s list of target markets. In his report to shareh= olders issued <st1:date Month=3D3 Day=3D1 Year=3D2002>= March 1, 2002</st1:date>, the President of Biotech Holdings, Robert <spa= n class=3DSpellE>Rieveley, said: We believe that we are well pos= itioned for receiving regulatory approval shortly.=FFFFFFA0 Accordingly, we have been making preparations for = supply of DIAB II to the Mexican market, which is the eighth largest pharm= aceutical market in the world.<o:p></o:p> <o:p></o:p></s= pan>In </= span><st1:place>Latin America</st1:place>, DIAB II has already b= een approved in <st1:country-region><st1:place>Peru</s= pan></st1:place></st1:country-region> and Biotech has signed = distribution agreements for <st1:country-region><st1:place><span= lang=3DEN-CA style=3D'font-size:9.0pt;mso-bidi-font-size:10.0pt;font-fami= ly: Arial'>Venezuela</st1:place></st1:country-region>= , <st1:country-region><st1:place>Chile</= b></st1:place></st1:country-region> and <st1:co= untry-region><st1:place>Argentina</st1:place></= st1:country-region>.=FFFFFFA0 = In other markets, a distributor has been signed for <st1:cou= ntry-region><st1:place>Turkey</st1:place></st1:= country-region> and preliminary agreements are in place for <= /span><st1:country-region><st1:place>Spain</st1:place></st1:country-region>, = <st1:country-region><st1:place>Greece</b= ></st1:place></st1:country-region>, <st1:countr= y-region><st1:place>South Africa</st1:place></s= t1:country-region> and several markets in the <st1:pla= ce>Middle East</st1= :place> and <st1:place>South Asia</st1:place>.</spa= n><o:p></o:p> <o:p></o:p><p= class=3DMsoNormal style=3Dtext-align:justify>The <st1= :country-region><st1:place>U.S.</st1:place></st1:country-region> pa= tents that protect DIAB II - - issued on <st1:date Month=3D11 Day=3D= 28 Year=3D2000>November 28, 2000</st1:date> and </= span><st1:date Month=3D9 Day=3D18 Year=3D2001>September 18, 2001</st= 1:date> - - confer the sole right to the use of treatments co= mbining insulin-sensitizing drugs with any other standard medications for = Type II Diabetes.=FFFFFFA0 Many l= arge pharmaceutical companies active in the diabetes field may be affected= <o:p></o:p> <o:p></o:p></spa= n>In addi= tion to its prescription drug business, Biotech has a non-prescription, pe= rsonal care products division which is showing steady growth.=FFFFFFA0 In addition to its growing private label= business, this division is planning to launch a new line of high-margin c= osmetic products, which will be sold primarily in the <st1:country-= region><st1:place>U.S.</st1:place></st1:country-region><o:p></o:p= >&= nbsp;<o:p></o:p>Biotech=FFFFFF92s revenues are set to grow= sharply as markets for DIAB II open up, as non-prescription rev= enues grow and as the implications of the above-mentioned patents are = pursued, with potential for royalty payments from major pharmaceutical = companies. In his Report to Shareholders, the President of Biotech con= cluded: We look forward with enthusiasm to developments in the coming m= onths.<o:p></o:p></p= ><h1 align=3Dleft style=3Dtext-align:left><o:p> </o:p></h1></td><td width=3D327 valign=3Dt= op style=3D'width:245.2pt;padding:0in 5.4pt 0in 5.4pt; height:549.0pt'><table class=3DMsoNormalTable border=3D0 cellspacing=3D0 c= ellpadding=3D0 align=3Dleft width=3D323 style=3D'width:242.6pt;border-coll= apse:collapse;mso-table-overlap: never;mso-table-lspace:9.0pt;margin-left:6.75pt;mso-table-rspace:9.0pt; margin-right:6.75pt;mso-table-anchor-vertical:paragraph;mso-table-anchor-h= orizontal: margin;mso-table-left:left;mso-table-top:97.8pt;mso-padding-alt:0in 5.4pt = 0in 5.4pt'><tr style=3Dmso-yfti-irow:0><td width=3D179 valign=3Dtop style=3D= 'width:134.6pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;background:green;padding:0in 5.4pt 0i= n 5.4pt'>Company Name<o:p></o:= p></td><td width=3D144 valign=3Dtop style=3D'width:1.5in;border= :solid windowtext 1.0pt; border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>Biotech Holdings Ltd.<o:p></o:p><= /span></td></tr><tr style=3Dmso-yfti-irow:1><td width=3D179 valign= =3Dtop style=3D'width:134.6pt;border:solid windowtext 1.0pt; border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-botto= m-alt: solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Stock Exchange in U.S= <o:p></o:p></td><td width=3D144 valign=3Dtop style=3D'width:1.5= in;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.= 0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowt= ext .5pt; mso-border-alt:solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt = 0in 5.4pt'>OTC BB: BIOHF<= span lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-b= idi-font-family: Arial'><o:p></o:p></td></tr><tr style=3Dmso-yfti-irow:2><td wid= th=3D179 valign=3Dtop style=3D'width:134.6pt;border:solid windowtext 1.0pt= ; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt'>Stock Exchange in </s= pan><st1:country-region><st1:place>Canada</st1:place></st1:country-region><o:p></o:p></td><td width=3D144 valign=3Dtop= style=3D'width:1.5in;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.= 0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowt= ext .5pt; mso-border-alt:solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt = 0in 5.4pt'>TS= X.Venture: BIO<o:p></o:p></p= ></td></tr><tr style=3Dmso-yfti-irow:3><td width=3D179 valign=3Dtop style=3D= 'width:134.6pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt'>52-week High/Low BIOH= F<o:p></o:p></td><td width=3D144 valign=3Dtop style=3D'width:1.= 5in;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.= 0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowt= ext .5pt; mso-border-alt:solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt = 0in 5.4pt'>$.41/$0.07<spa= n lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-bidi= -font-family: Arial'><o:p></o:p></td></tr><tr style=3Dmso-yfti-irow:4;mso-yft= i-lastrow:yes><td width=3D179 valign=3Dtop style=3D'width:134.6pt;border:s= olid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt'>52-week High/Low BIO<= o:p></o:p></td><td width=3D144 valign=3Dtop style=3D'width:1.5i= n;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.= 0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowt= ext .5pt; mso-border-alt:solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt = 0in 5.4pt'>$.65/$.12<span= lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-bidi-= font-family: Arial'><o:p></o:p></td></tr></table><o:p> </o:p><o:p> </o:p>= <o:p> </o:p><o:p>&= nbsp;</o:p><o:p> <= /o:p><o:p> </o:p><= /span><table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpad= ding=3D0 style=3D'background:#E5D68D;border-collapse:collapse;mso-padding-= alt:0in 5.4pt 0in 5.4pt'><tr style=3Dmso-yfti-irow:0;mso-yfti-lastrow:yes>= <td width=3D324 valign=3Dtop style=3D'width:242.65pt;padding:0in 5.4pt 0in= 5.4pt'><h1 align=3Dleft style=3D'text-align:left;tab-stops:12.75pt center= 115.9pt'>=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFF= FA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA= 0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0 THE <st1:place>OPPORTUNITY</sp= an></st1:place><o:p></o:p></h1></td></tr></table><o:p> </o:= p><h1 align=3Dcenter style=3Dtext-align:center>There has been growing investor interest and substantial volumes in = trading of BIOHF shares.=FFFFFFA0 Si= nce January 2002 trading has averaged nearly 1 million shares per week.<sp= an style=3Dmso-spacerun:yes>=FFFFFFA0 This suggests to some market = watchers that a strong base is being formed, with the next step being a si= gnificant upward movement.=FFFFFFA0=FFFFFFA= 0 Research the growth potential of this special situation while the= Company that developed, controls and markets DIAB II is still trading as = a penny stock.<o:p></o:p></h1><o:p> </o:p>= <o:p> </o:p><table class=3DMsoNormalTable border=3D0 cells= pacing=3D0 cellpadding=3D0 style=3D'background:#E5D68D;border-collapse:col= lapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'><tr style=3Dmso-yfti-irow:0;mso= -yfti-lastrow:yes><td width=3D324 valign=3Dtop style=3D'width:242.65pt;pad= ding:0in 5.4pt 0in 5.4pt'><h2 align=3Dcenter style=3Dtext-align:center><sp= an lang=3DEN-CA style=3D'font-family:"Calisto MT";color:green'>INVESTOR IN= FORMATION<o:p></o:p><= /h2></td></tr></table><o:p> </o:p><table class=3DMsoNormalTable= border=3D0 cellspacing=3D0 cellpadding=3D0 width=3D332 style=3D'width:249= 0pt;border-collapse:collapse;mso-padding-alt:0in 5.4pt 0in 5.4pt'><tr sty= le=3Dmso-yfti-irow:0><td width=3D192 valign=3Dtop style=3D'width:144.2pt;b= order:none;border-bottom: solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Active Float:<o:p></o:p></td><td widt= h=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border-bottom: solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>20,000,000<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:1><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'><st1:country-region><st1:place>U.S.</st1:place></st1:country-region> SEC Registration No.:<o:p></o:p><= /p></td><td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;bo= rder-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>0 - 29108<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:2><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Shares outstandingMar.31/02:<o:p></o:p><= /p></td><td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;bo= rder-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>69,928,130<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:3><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Recent Market Cap:<o:p></o:p></td><= td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border-bott= om: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>$6,300,000 US<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:4><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Stock Exchange in <st1:country-region><st1:place><span= lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-bidi-= font-family: Arial;color:white'>U.S.</st1:place></st1:country-region>:<o:p></o:p></td><td widt= h=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>OTC BB: BIOHF<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:5><td width=3D192 valign=3Dtop style=3D'width:144.2pt;border:no= ne;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>Stock Exchange in <st1:country-region><st1:place><span= lang=3DEN-CA style=3D'font-size:10.0pt;font-family:"Calisto MT";mso-bidi-= font-family: Arial;color:white'>Canada</st1:place></st1:country-region>:<o:p></o:p></td><td widt= h=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>TSX.Venture:BIO<span= lang=3DEN-CA style=3Dfont-size:10.0pt;mso-bidi-font-size:12.0pt><o:p></o:= p></td></tr><tr style=3Dmso-yfti-irow:6><td width=3D192 valign=3D= top style=3D'width:144.2pt;border:none;border-bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:green;padding:0in 5.4pt 0in 5.4pt'>52-week High/Low BIOHF:<o:p></o:p><= /td><td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;border= -bottom: solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;mso-border= -top-alt: solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt; background:#E5D68D;padding:0in 5.4pt 0in 5.4pt'>$.41/$0.07<o:p></o:p></td></tr><tr style=3Dmso= -yfti-irow:7;mso-yfti-lastrow:yes;height:3.5pt><td width=3D192 valign=3Dto= p style=3D'width:144.2pt;border:none;mso-border-top-alt: solid windowtext .5pt;background:green;padding:0in 5.4pt 0in 5.4pt; height:3.5pt'>52-week High/Low BIO:<o:p></o:p></td><= td width=3D140 valign=3Dtop style=3D'width:104.8pt;border:none;mso-border-= top-alt: solid windowtext .5pt;background:#E5D68D;padding:0in 5.4pt 0in 5.4pt; height:3.5pt'>$.65/$.12<o:p></o:p></td></tr></table><o:p> </o:p>= =FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFF= FA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA= 0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FF= FFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFF= FFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFF= A0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0= =FFFFFFA0=FFFFFFA0=FFFFFFA0=FFFFFFA0</td></tr></tabl= e>Th= e Investment Journal: The information herein has been obtained from source= s which are believed to be reliable, but there are no guarantees as to its= accuracy or completeness. Neither the information nor any opinion express= ed constitutes a solicitation for the purchase or sale of any security. Bi= otech Holdings has not paid any cash or shares for its appearance on this = report.=FFFFFFA0 Some or all employe= es at The Investment Journal may hold shares in companies featured. We do = not recommend or constitute "buy" or "sell" signals or= advisories for our readers. The Investment Journal is not a securities br= oker-dealer, investment advisor or a securities exchange and is not regist= ered as such with the Securities and Exchange Commission nor any state securities regulation authority. Consult with your= financial advisor before making any financial decisions.This Newsletter is inte= nded for our opt-in readers only. If you have received this email in error= ,<o:p></o:p>=FFFFFFA0you may remove your address by e-mailing <a = href=3Dmailto:theinvestmentjournal@excite.com?subject=3DRemove>theinvestme= ntjournal@excite.com</a>.<o:p></o:p><o:p> </o:p><= /div></body></html>